Tags

Type your tag names separated by a space and hit enter

Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
J Pharmacol Exp Ther. 1982 Jul; 222(1):276-81.JP

Abstract

The relative contribution of thromboxane (TX)A2/prostaglandin (PG)H2 and ADP to platelet shape change was determined using the specific TXA2/PGH2 antagonist, 13-azaprostanoic acid (13-APA) and the ADP antagonist, ATP. Shape change was induced in human platelet-rich plasma with doses of arachidonic acid (AA) or the PG endoperoxide analog U46619, which did not cause measurable ATP/ADP release. Pretreatment of platelet-rich plasma with 13-APA completely inhibited shape change to AA or U46619 but did not inhibit ADP-induced shape change. In contrast, ATP completely blocked shape change to ADP but not to AA or U46619. In addition, 13-APA and ATP also selectively reversed shape change. Thus, 13-APA added 1.5 min subsequent to AA or U46619 resulted in almost complete reversal of the shape change response. However, 13-APA did not reverse ADP-induced shape change. A similar selectivity was observed with ATP which reversed shape change to ADP but not to AA or U46619. These findings provide evidence that the interaction of TXA2/PGH2 with its receptor results in the direct stimulation of shape change independent of secreted ADP. Furthermore, maintenance of this shape change response appears to require continued occupation of the TXA2/PGH2 receptor.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

7086705

Citation

Parise, L V., et al. "Thromboxane A2/prostaglandin H2 Directly Stimulates Platelet Shape Change Independent of Secreted ADP." The Journal of Pharmacology and Experimental Therapeutics, vol. 222, no. 1, 1982, pp. 276-81.
Parise LV, Venton DL, Le Breton GC. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP. J Pharmacol Exp Ther. 1982;222(1):276-81.
Parise, L. V., Venton, D. L., & Le Breton, G. C. (1982). Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP. The Journal of Pharmacology and Experimental Therapeutics, 222(1), 276-81.
Parise LV, Venton DL, Le Breton GC. Thromboxane A2/prostaglandin H2 Directly Stimulates Platelet Shape Change Independent of Secreted ADP. J Pharmacol Exp Ther. 1982;222(1):276-81. PubMed PMID: 7086705.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP. AU - Parise,L V, AU - Venton,D L, AU - Le Breton,G C, PY - 1982/7/1/pubmed PY - 1982/7/1/medline PY - 1982/7/1/entrez SP - 276 EP - 81 JF - The Journal of pharmacology and experimental therapeutics JO - J Pharmacol Exp Ther VL - 222 IS - 1 N2 - The relative contribution of thromboxane (TX)A2/prostaglandin (PG)H2 and ADP to platelet shape change was determined using the specific TXA2/PGH2 antagonist, 13-azaprostanoic acid (13-APA) and the ADP antagonist, ATP. Shape change was induced in human platelet-rich plasma with doses of arachidonic acid (AA) or the PG endoperoxide analog U46619, which did not cause measurable ATP/ADP release. Pretreatment of platelet-rich plasma with 13-APA completely inhibited shape change to AA or U46619 but did not inhibit ADP-induced shape change. In contrast, ATP completely blocked shape change to ADP but not to AA or U46619. In addition, 13-APA and ATP also selectively reversed shape change. Thus, 13-APA added 1.5 min subsequent to AA or U46619 resulted in almost complete reversal of the shape change response. However, 13-APA did not reverse ADP-induced shape change. A similar selectivity was observed with ATP which reversed shape change to ADP but not to AA or U46619. These findings provide evidence that the interaction of TXA2/PGH2 with its receptor results in the direct stimulation of shape change independent of secreted ADP. Furthermore, maintenance of this shape change response appears to require continued occupation of the TXA2/PGH2 receptor. SN - 0022-3565 UR - https://www.unboundmedicine.com/medline/citation/7086705/Thromboxane_A2/prostaglandin_H2_directly_stimulates_platelet_shape_change_independent_of_secreted_ADP_ DB - PRIME DP - Unbound Medicine ER -